Effect of spironolactone on acute mountain sickness.

Abstract

This study examined the effectiveness of spironolactone as a prophylactic agent for the prevention of acute mountain sickness (AMS). Spironolactone, 25 mg PO QID, or placebo was administered to nine subjects in a double-blind, placebo-controlled, crossover design. Medication was given for 48 h prior to and during a 46-h exposure to 427 mm Hg (4570 m) in a hypobaric chamber. Six subjects demonstrated prevention of either the cerebral or respiratory symptoms of AMS during at least one segment of the altitude sojourn.

• Authors: R F Larsen, P B Rock, C S Fulco, B Edelman, A J Young, A Cymerman
• Journal: Aviation, space, and environmental medicine (Aviat Space Environ Med) Vol. 57 Issue 6 Pg. 543-7 (Jun 1986) ISSN: 0095-6562 [Print] United States
• PMID: 3718378 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Placebos
• Spironolactone

Topics

• Acute Disease
• Adult
• Double-Blind Method
• Humans
• Hypoxia (prevention & control)
• Male
• Placebos
• Random Allocation
• Spironolactone (therapeutic use)
• Time Factors